The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2015: Volume 20/ Issue 5 Article 3
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 20, Issue 5, 05 February 2015
Rapid communications
Reduced cross-protection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine
  1. Viral Infections Unit, Department of Infectious Diseases, National Institute for Health and Welfare, Helsinki, Finland
  2. Department of Virology, University of Turku, Turku, Finland
  3. Division of Infectious Diseases, Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
  4. Vaccination Programme Unit, Department of Health Protection, National Institute for Health and Welfare, Helsinki, Finland
  5. Infectious Disease Control Unit, Department of Infectious Diseases, National Institute for Health and Welfare, Helsinki, Finland

Citation style for this article: Haveri A, Ikonen N, Julkunen I, Kantele A, Anttila VJ, Ruotsalainen E, Nohynek H, Lyytikäinen O, Savolainen-Kopra C. Reduced cross-protection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine. Euro Surveill. 2015;20(5):pii=21028. Article DOI:
Date of submission: 26 January 2015

Virus strains in the seasonal influenza vaccine for the 2014/15 northern hemisphere season remained unchanged from those in 2013/14. During spring 2014, drifted influenza A(H3N2) viruses, subgroup 3C.3a, were detected in Finland; another subgroup, 3C.2a, emerged in the 2014/15 season and has predominated. We monitored antibody responses against vaccine and epidemic strains (2013/14 and 2014/15) among Finnish healthcare workers after influenza vaccination with the 2013/14 vaccine. The data suggest reduced cross-protection towards both subgroups of drifted A(H3N2) viruses.

Early in the 2014/15 influenza season, drifted influenza A(H3N2) viruses have predominated in Europe [1,2]. In Finland, the season started earlier in the year than the previous season did (December 2014 as opposed to January 2014). We characterised a subset of circulating 2013/14 and 2014/15 influenza A(H3N2) viruses genetically to monitor changes in the circulating strains. On the basis of the genetic changes identified, representatives of these strains were selected for serological study. The strains recommended by the World Health Organization (WHO)  for inclusion in the 2014/15 trivalent influenza vaccine (TIV) for the northern hemisphere [3] are the same as those in 2013/14 [4]: A/California/07/2009, A/Texas/50/2012 and B/Massachusetts/02/2012. By exploring the antibody responses to the 2013/14 TIV in Finnish healthcare workers (HCWs), we evaluated the seroprotection level against viruses included in TIV and compared it with vaccine-induced cross-protection towards selected epidemic virus strains from the 2013/14 and 2014/15 seasons. Our findings suggest reduced cross-protection towards the two subgroups of drifted A(H3N2) viruses detected in Finland (genetic subgroups 3C.3a and 3C.2).

Genetic characterisation of influenza A(H3N2) viruses in Finland in 2013/14 and 2014/15

As part of virological surveillance of influenza in Finland, a subset of influenza A(H3N2)-positive samples from sites in a sentinel influenza surveillance network and non-sentinel sites are  selected throughout the season for genetic characterisation on the basis of their geographical origin and temporal distribution.

The sentinel network consists of healthcare centres collecting specimens from patients with influenza-like illness or acute respiratory infection and most also report clinical data. Healthcare centres of garrisons, also included in the network, only collect specimens. While intensive-care units are also part of the network, collecting specimens only, they are not considered as sentinel sites, as their participation is not agreed in advance (unlike that of healthcare centres). Other non-sentinel sites include clinical microbiology laboratories, for example. 

Phylogenetic analysis of the haemagglutinin gene was performed as described previously [5]. Reference influenza A(H3N2) virus sequences for the phylogenetic tree were obtained from the EpiFlu database of the Global Initiative on Sharing Avian Influenza Data (GISAID) (Table 1).

Table 1. Origin of the haemagglutinin sequence information of influenza A(H3N2) viruses included in the phylogenetic analysis 

During the 2013/14 season, a total of 27 influenza A(H3N2) viruses were analysed: 25 belonged to group 3C.3 and two to group 3C.2 (Figure 1, Table 1). Of the 25 group 3C.3 viruses, six represented a new drifted A(H3N2) type, group 3C.3a viruses. In Finland, these viruses were first detected in February 2013.

At the beginning of the 2014/15 season, all nine influenza A(H3N2) viruses analysed belonged to another drifted group, 3C.2a.

Figure 1. Phylogenetic analysis of the haemagglutinin sequences of influenza A(H3N2) viruses from Finnish surveillance data during two epidemic seasons, 2013/14 and 2014/15

Monitoring antibody response after influenza vaccination in a cohort of healthcare workers

A total of 79 clinically healthy HCWs (12 men, 67 women), median age 46 years (range: 22–66), were recruited on a voluntary basis during autumn 2013 from the personnel of the Department of Medicine at the Helsinki University Hospital and the Viral Infections Unit at the National Institute for Health and Welfare, Helsinki. The employer vaccinated each participant with the 2013/14 seasonal influenza vaccine, which was trivalent, non-adjuvanted, containing the three WHO-recommended influenza virus strains. One dose was administered intramuscularly. Serum samples were collected before vaccination (day 0) and three weeks and six months after vaccination.

The study protocol was approved by the Ethic Committee of the Department of Medicine, Helsinki University Hospital (298/13/03/00/12) and the Finnish Medicines Agency (EudraCT 2012–003727–38). Written informed consent was provided by all participants.

The serum samples were tested by the haemagglutination inhibition (HI) test for the presence of antibodies against TIV vaccine viruses and Finnish influenza virus isolates from the 2013/14 and 2014/15 seasons. TIV strains for the northern hemisphere 2013/14 and 2014/15 seasons were A/California/07/2009 (group 1), A/Texas/50/2012 (group 3C.1) and B/Massachusetts/02/2012 (clade 2). For comparison, we also included B/Wisconsin/01/2010 (clade 3), the vaccine strain for the northern hemisphere 2012/13 season, and A/Switzerland/9715293/2013 (H3N2) (group 3C.3a), the vaccine strain for the southern hemisphere 2015 season. We also included A/Finland/420/2014 (group 6B), which represented the Finnish A(H1N1)pdm09 strain that circulated in 2013/14. In addition, A/Finland/385/2013 (2013/14), A/Finland/428/2014 (2013/14) and A/Finland/464/2014 (2014/15) were selected as representative of circulating Finnish A(H3N2) viruses for groups 3C.3, 3C.3a and 3C.2a, respectively.

The assay was performed as previously described [6] using erythrocytes from turkeys for A(H1N1)pdm09 viruses and guinea pigs for A(H3N2) and influenza B viruses. A(H3N2) viruses were assayed in the presence of 20 nM oseltamivir carboxylate (Roche). For statistical analyses, serum specimens with HI titres < 10 were assigned a titre value of 5. We calculated the geometric mean titres (GMT) with 95% confidence intervals and presumable seroprotection rate (using the commonly accepted European Medicines Agency criteria [7]: HI titre ≥ 1:40) for each virus. Statistical significance of differences was estimated using Student’s t-test (paired, two-tailed), with a significance level of p < 0.05.

For all virus strains tested, there was a significant (p < 0.01) increase in the GMTs of the antibody response three weeks after TIV vaccination (Table 2). At six months, the GMTs decreased by 39.4–46.2%, 24.4–42.3% and 11.9–18.4% for influenza A(H1N1)pdm09, A(H3N2) and B viruses, respectively. The decrease was significant (p < 0.05 to p < 0.001) for both types influenza A viruses.

Table 2. Geometric mean titres against influenza A(H1N1)pdm09, A(H3N2) and B viral strains measured by haemagglutination inhibition test before and after vaccination of 79 healthcare workers with 2013/14 trivalent influenza vaccine, Finland

The baseline seroprotection rate for A(H1N1)pdm09 viruses was 57.0–58.2% (Figure 2). Three weeks after vaccination, the GMTs were higher for the recently circulating A/Finland/420/2014 strain than for the vaccine strain (p < 0.05). Post-vaccination seroprotection rates were 89.6% and 85.7% for A/Finland/420/2014 and A/California/07/2009 viruses, respectively.

Figure 2. Seroprotection rates determined by haemagglutination inhibition test before and after vaccination of 79 healthcare workers with 2013/14 trivalent influenza vaccine, Finland

The seroprotection rate for A(H3N2) vaccine virus A/Texas/50/2012 was 60.8% before vaccination and 87.0% three weeks after it. Three weeks post-vaccination, the GMTs were somewhat weaker for A/Finland/385/2013, a Finnish representative of group 3C.3 virus strains, than to the vaccine strain (p < 0.01). Significantly lower GMTs were detected for the group 3C.3a strain A/Switzerland/9715293/2013 as well as the Finnish group 3C.3a strain A/Finland/428/2014 and recently circulating group 3C.2a strain A/Finland/464/2014 compared with the vaccine strain (p < 0.0001).

For drifted Finnish 3C.3a and 3C.2a viruses, baseline seroprotection rates were low (8.9% and 1.3%, respectively) and fivefold reductions in GMTs (for both) were detected three weeks after vaccination, compared with the vaccine strain. The reduction in GMTs for A/Finland/428/2014 (group 3C.3a) was in line with recently reported HI and neutralisation levels [8,9].

The baseline seroprotection rate for influenza B viruses was 26.6–27.8%. Three weeks after vaccination, very similar  seroprotection rates were seen for vaccine strains B/Massachusetts/2/12 (61.0%) and B/Wisconsin/01/2010 (59.7%), which both represent the Yamagata-lineage viruses but belong to different clades.


During the 2013/14 season, the relative prevalence of A(H1N1)pdm09, A(H3N2) and B influenza viruses varied from one European country to another [10]. In Finland, A(H1N1)pdm09 viruses predominated but A(H3N2) viruses were also detected. Most of the circulating A(H1N1)pdm09 and A(H3N2) viruses corresponded well with those included in the seasonal TIV vaccine for that season. Viruses from patients requiring intensive care were not proven genetically different from other circulating viruses [11].

Representatives of influenza A(H3N2) groups 3C.2 and 3C.3 were found in Europe in the 2013/14 season and since February 2014, two new genetic subgroups, 3C.2a and 3C.3a, emerged in these clusters [8,10]. Both of these genetic subgroups contain viruses that show antigenic drift from the vaccine virus [1]. In Finland, infections caused by A(H3N2) genetic subgroup 3C.3a viruses were detected between February and April 2014. Genetic subgroup 3C.2a viruses, in contrast, did not circulate in Finland during the 2013/14 season but only emerged in the 2014/15 season.

Drifted influenza A(H3N2) viruses have been circulating in the countries of the European Union and European Economic Area in the 2014/15 season. The majority of genetically characterised viruses belong to group 3C.2a although 3C.3a viruses have also been detected [1]. In the United States (US), the Centers for Disease Control and Prevention has issued a health advisory notice regarding the circulation of drifted influenza A(H3N2) viruses in the US [12]. Early estimates of the current seasonal influenza vaccine effectiveness from the US and Canada suggest low effectiveness against circulating A(H3N2) viruses [13,14].

New antigenic A(H3N2) clusters appear on average every 3.3 years [15]. Seven amino acid locations have been shown to be responsible for the major antigenic changes in A(H3N2) viruses [16]. Subgroup 3C.2a and 3C.3a viruses carry specific amino acid substitutions that drifted from the corresponding main groups. Both subgroups have a substitution at position 159, which has shown to be one of seven positions responsible for the major antigenic changes between 1968 and 2003 A(H3N2) viruses [16].

In our analysis of antibody response, GMTs against the circulating A/Finland/428/2014 virus (a group 3C.3a A(H3N2) virus) were found to be significantly lower than GMTs against the homologous A/Texas/50/2012 vaccine virus. These results are in line with those from Finnish A(H3N2) variant strains tested in WHO Collaborating Centre for Reference and Research on Influenza, in London, United Kingdom, using HI and virus neutralisation assays [9] and previous serological studies [8]. The pre-vaccination seroprotection rate of the HCWs we tested for this virus variant was only less than 10%. Even at three weeks after vaccination, the cross-protection rate was only less than 30% and decreased to less than 10% within 6 months.

The GMTs were found to be significantly lower against the currently circulating subgroup 3C.2a A(H3N2) virus A/Finland/464/2014 than against the homologous A/Texas/50/2012 vaccine virus. Only one of the 79 HCWs tested had pre-existing seroprotective antibody levels against this virus variant. Three weeks after vaccination, the cross-protection rate was 16.9% and decreased to less than 2% within six months. Subgroup 3C.2a viruses have also shown to have poor reactivity with post-infection ferret antisera against vaccine virus A/Texas/50/2012 [17].

Although influenza A(H1N1)pdm09 viruses have undergone genetic changes from the A/California/07/2009 strains present in the vaccine, the majority of epidemic viruses in Europe have been antigenically similar to the vaccine virus [2,10]. Our serological results indicate a strong vaccine-induced seroprotection rate against A(H1N1)pdm09 viruses. Consistent with this, more than half of the Finnish HCWs tested had pre-existing immunity against A(H1N1)pdm09 viruses. This may be due to the history of sequential TIV vaccinations in the study group or natural infections by A(H1N1)pdm09 viruses.

We acknowledge at least a few limitations in our serological analysis. First, the number of HCWs included in the study was limited. Secondly, the HCWs we tested did not represent all age groups: thus the results do not necessarily apply to children or elderly individuals. Antibody responses to influenza A(H1N1)pdm09 vaccination are age dependent [18] and low vaccine effectiveness against A(H3N2) has been reported among elderly persons [19]. For influenza B viruses, the overall impact of lineage-level mismatch between vaccine and circulating strains has been shown to be considerable, especially among children and adolescents [20]. Thirdly, HCWs are often vaccinated more regularly than others (in Finland, influenza vaccination is recommended for all HCWs who come in contact with patients) and they are also at higher risk of contracting influenza virus. The impact of repeated vaccination on vaccine effectiveness against influenza is still under investigation and discussion [21,22].

In conclusion, our serological data suggest that although the 2013/14 and 2014/15 TIV would protect against A(H1N1)pdm09 viruses, the protection against influenza A(H3N2) 3C.2a and 3C.3a virus variants would be suboptimal. The current epidemic situation in the northern hemisphere underlines the need to change the A(H3N2) component of the 2015/16 vaccine to a virus that represents one of the drifted groups. With minimal pre-existing immunity and a limited cross-protective effect from the TIV, the population in the northern hemisphere may be more susceptible to the new influenza A(H3N2) virus variants during the current 2014/15 season. However, influenza vaccination is strongly encouraged for HCWs, as well as for persons in risk groups, to reduce influenza disease burden and the spread of the epidemics.
We would like to thank sentinel surveillance network and intensive-care units for their contribution in providing swab specimens. The WHO Collaborating Centre at the National Institute for Medical Research, London, UK, is acknowledged for providing TIV viruses used in the HI test and for all support and information. We thank all volunteers for their contribution in providing sera. Furthermore, we thank Riitta Santanen, Minna Haanpää, Esa Rönkkö, Alena Kaijalainen, Päivi Hirttiö, Teija Aalto, Mervi Eskelinen and Outi Rautio for their expert technical assistance, and Tarja Silvasti for help in the recruitment process. The study was supported by the funds from the National Institute for Health and Welfare. The funding agency had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. 

We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID’s EpiFlu database. All submitting laboratories may be contacted directly via the GISAID website

Conflicts of interest
None declared.

Authors’ contributions
All authors have contributed to, seen and approved the manuscript. AH performed the serological data analysis and wrote the draft manuscript. NI made the genetic characterisations and participated in the writing of the manuscript. IJ, ER, AK and VJA were involved in the design of TIV vaccination study and sera collections. OL and HN provided their comments and participated in discussions. CSK was responsible for the viral laboratory facility and participated in the writing of the manuscript.

  1. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment. Circulation of drifted influenza A(H3N2) viruses in the EU/EEA - 22 December 2014. Stockholm: ECDC; 2014. Available from:
  2. Broberg E, Snacken R, Adlhoch C, Beauté J, Galinska M, Pereyaslov D, et al. Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype. Euro Surveill. 2015;20(4):21023. Available from:
  3. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. Geneva: WHO; 20 Feb 2014. Available from:
  4. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2013-2014 northern hemisphere influenza season. Geneva: WHO; 21 Feb 2013. Available from:
  5. Ikonen N, Haanpää M, Rönkkö E, Lyytikäinen O, Kuusi M, Ruutu P, et al. Genetic diversity of the 2009 pandemic influenza A(H1N1) viruses in Finland. PLoS ONE. 2010;5(10):e13329. PMID:20975994
  6. World Health Organization (WHO). Global influenza surveillance network. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO; 2011. Available from:
  7. Committee for proprietary medicinal products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. London: European Medicines Agency; 12 March 1997. Available from:
  8. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2015 southern hemisphere influenza season. Geneva: WHO; 25 Sep 2014. Available from:
  9. National Institute for Medical Research. WHO Influenza Centre London. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Southern Hemisphere 2015. 22 – 24 September 2014. London: WHO Collaborating Centre for Reference and Research on Influenza, National Institute for Medical Research; 2014. Available from:
  10. European Centre for Disease Prevention and Control (ECDC). Surveillance report. Influenza virus characterisation. Summary Europe, July 2014. Stockholm: ECDC; 2014. Available from:
  11. Ikonen N, Murtopuro S, Virtanen M, Jokinen J, Baum U, Syrjänen R, et al. Influenssakausi Suomessa, viikot 40/2013-20/2014 - Seurantaraportti. Työpaperi: 2014_025.  [Surveillance report. Influenza season in Finland, weeks 40/2013-20/2014.] Tampere: Terveyden ja hyvinvoinnin laitos; 2014. [Finnish]. Available from:
  12. Centers for Disease Control and Prevention (CDC). CDC Health Advisory Regarding the Potential for Circulation of Drifted Influenza A (H3N2) Viruses. Atlanta, GA: CDC; 3 Dec 2014. Available from:
  13. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015;64(1):10-5. PMID:25590680
  14. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4):21022. Available from:
  15. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305(5682):371-6. PMID:15218094
  16. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976-9. PMID:24264991
  17. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterization. Summary Europe, November 2014. Stockholm: ECDC; 2014. Available from:
  18. Strengell M, Ikonen N, Ziegler T, Kantele A, Anttila VJ, Julkunen I. Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals. Influenza Other Respi Viruses. 2013;7(3):431-8. PMID:22913369
  19. Bragstad K, Emborg H, Fischer TK, Voldstedlund M, Gubbels S, Andersen B, et al. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13--a rapid epidemiological and virological assessment. Euro Surveill. 2013;18(6):20397. Available from: PMID:23410258
  20. Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clin Infect Dis. 2014;59(11):1519-24. PMID:25139969
  21. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59(10):1375-85. PMID:25270645
  22. Neuzil KM. How can we solve the enigma of influenza vaccine-induced protection? J Infect Dis. 2014;pii: jiu651. 10.1093/infdis/jiu651 PMID:25416811

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.